Does the pathophysiology of heart failure prime the incidence of cancer?
Mari Sakamoto(National Cerebral and Cardiovascular Center), Masafumi Kitakaze(Hanwa Memorial Hospital), Naoki Mochizuki(National Cerebral and Cardiovascular Center), Toshihisa Anzai(Hokkaido University), Masanori Asakura(National Cerebral and Cardiovascular Center), Toshimitsu Hamasaki(National Cerebral and Cardiovascular Center), Makoto Amaki(National Cerebral and Cardiovascular Center), Hiroyuki Takahama(Tohoku University), Takuya Hasegawa(National Cerebral and Cardiovascular Center), Hideaki Kanzaki(National Cerebral and Cardiovascular Center)
Cited by 56
Related Papers
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: Metalloproteinase inhibitors as a new therapy
|Nature Medicine|2002|722
Right Ventricular Function in Heart Failure With Preserved Ejection Fraction
|Circulation|2014|456
Cyclic AMP Potentiates Vascular Endothelial Cadherin-Mediated Cell-Cell Contact To Enhance Endothelial Barrier Function through an Epac-Rap1 Signaling Pathway
|Molecular and Cellular Biology|2004|414